Two Sigma Investments, LP Biomarin Pharmaceutical Inc Put Options Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $7.2 Million - $8.93 Million	-96,800 Reduced 53.69%	83,500 $6.87 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $796,195 - $940,500	-9,500 Reduced 5.01%	180,300 $15.7 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $14.5 Million - $18.7 Million	189,800 New	189,800 $18.3 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $29,908 - $34,188	-400 Reduced 9.09%	4,000 $309,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $332,244 - $373,076	4,400 New	4,400 $367,000
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $237,171 - $432,399	-3,300 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $532,985 - $832,274	-6,700 Reduced 67.0%	3,300 $407,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $356,850 - $484,250	5,000 Added 100.0%	10,000 $845,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $462,744 - $621,864	-7,200 Reduced 59.02%	5,000 $423,000
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $283,080 - $357,462	-4,200 Reduced 25.61%	12,200 $822,000
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $1.32 Million - $1.54 Million	16,400 New	16,400 $1.41 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.